Workflow
Compared to Estimates, Vertex (VRTX) Q2 Earnings: A Look at Key Metrics
VertexVertex(US:VRTX) ZACKSยท2024-08-02 23:01

Core Insights - Vertex Pharmaceuticals reported $2.65 billion in revenue for Q2 2024, a year-over-year increase of 6.1% [1] - The company experienced an EPS of -$12.83, a significant decline from $3.89 a year ago, with an EPS surprise of -11.57% [1][2] - The reported revenue was in line with the Zacks Consensus Estimate, showing a slight surprise of -0.08% [1] Revenue Breakdown - Geographic Revenues in the United States reached $1.61 billion, exceeding the estimated $1.59 billion, reflecting a +7.1% change year-over-year [3] - Geographic Revenues outside the United States were $1.03 billion, matching the analyst estimate and showing a +4.7% change from the previous year [4] - Revenues from the product Trikafta/Kaftrio totaled $2.45 billion, aligning with the seven-analyst average estimate and representing a +9.3% year-over-year increase [5] - Revenues from other CF products amounted to $196.40 million, surpassing the two-analyst average estimate of $179.54 million [6] Stock Performance - Vertex shares have returned +7.6% over the past month, contrasting with the Zacks S&P 500 composite's -0.4% change [6] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [6]